Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models

Background: Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models. Method: We design in vitro and in vivo m...

Descripción completa

Detalles Bibliográficos
Autores: Hijona Muruamendiaraz, Elizabeth, Bañales Asurmendi, Jesús María, Hijona Muruamendiaraz, Lander, Medina, Juan F., Arenas Mirave, Juan Ignacio, Herreros Villanueva, Marta, Aldazabal, Pablo, Bujanda Fernández de Pierola, Luis
Tipo de recurso: artículo
Fecha de publicación:2012
País:España
Institución:Universidad del País Vasco
Repositorio:Addi. Archivo Digital para la Docencia y la Investigación
OAI Identifier:oai:addi.ehu.eus:10810/7326
Acceso en línea:http://hdl.handle.net/10810/7326
Access Level:acceso abierto
Palabra clave:pravastatin
sorafenib
hepatocarcinoma
statins
GENETICS AND HEREDITY
ONCOLOGY
id ES_8a350e607b521e01b9d8d856b86bbfef
oai_identifier_str oai:addi.ehu.eus:10810/7326
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo modelsHijona Muruamendiaraz, ElizabethBañales Asurmendi, Jesús MaríaHijona Muruamendiaraz, LanderMedina, Juan F.Arenas Mirave, Juan IgnacioHerreros Villanueva, MartaAldazabal, PabloBujanda Fernández de Pierola, LuispravastatinsorafenibhepatocarcinomastatinsGENETICS AND HEREDITYONCOLOGYBackground: Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models. Method: We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we used and animal model to determined, PCNA and MAT1A expression and transaminases levels. Results: We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L). Conclusion: The combination of pravastatin + sorafenib were more effective than Sorafenib alone.CIBFRehd is funded by the Carlos III Health Institute. In addition, this work was supported by grants from the Department of Health of the Basque Government 2009/111003.BioMed Central201220122012info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10810/7326reponame:Addi. Archivo Digital para la Docencia y la Investigacióninstname:Universidad del País VascoIngléshttp://www.cancerci.com/content/12/1/5info:eu-repo/semantics/openAccess© 2012 Hijona et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.oai:addi.ehu.eus:10810/73262026-06-18T09:23:17Z
dc.title.none.fl_str_mv Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
title Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
spellingShingle Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
Hijona Muruamendiaraz, Elizabeth
pravastatin
sorafenib
hepatocarcinoma
statins
GENETICS AND HEREDITY
ONCOLOGY
title_short Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
title_full Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
title_fullStr Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
title_full_unstemmed Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
title_sort Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
dc.creator.none.fl_str_mv Hijona Muruamendiaraz, Elizabeth
Bañales Asurmendi, Jesús María
Hijona Muruamendiaraz, Lander
Medina, Juan F.
Arenas Mirave, Juan Ignacio
Herreros Villanueva, Marta
Aldazabal, Pablo
Bujanda Fernández de Pierola, Luis
author Hijona Muruamendiaraz, Elizabeth
author_facet Hijona Muruamendiaraz, Elizabeth
Bañales Asurmendi, Jesús María
Hijona Muruamendiaraz, Lander
Medina, Juan F.
Arenas Mirave, Juan Ignacio
Herreros Villanueva, Marta
Aldazabal, Pablo
Bujanda Fernández de Pierola, Luis
author_role author
author2 Bañales Asurmendi, Jesús María
Hijona Muruamendiaraz, Lander
Medina, Juan F.
Arenas Mirave, Juan Ignacio
Herreros Villanueva, Marta
Aldazabal, Pablo
Bujanda Fernández de Pierola, Luis
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv pravastatin
sorafenib
hepatocarcinoma
statins
GENETICS AND HEREDITY
ONCOLOGY
topic pravastatin
sorafenib
hepatocarcinoma
statins
GENETICS AND HEREDITY
ONCOLOGY
description Background: Statins may have therapeutic effects on hepatocarcinoma (HCC). This type of disorder is the most common malignant primary tumour in the liver. Our objective was to determine whether pravastatin had a therapeutic effect in vitro and in vivo models. Method: We design in vitro and in vivo model. In vitro we used PLC and determine cell proliferation. In vivo, we used and animal model to determined, PCNA and MAT1A expression and transaminases levels. Results: We found that pravastatin decreases cell proliferation in vitro (cell proliferation in pravastatin group was 82%, in sorafenib group 51% and in combined group 40%) and in vivo (in pravastatin group 80%, in sorafenib group 76.4% and in combined group 72.72%). The MAT1A levels, was significantly higher in Pravastatin group (D 62%, P 94%, S 71%, P + S 91%). The transaminases levels, decreased significantly in Pravastatin group (GOT and GPT levels D 619.5 U/L; 271 U/L) (P 117.5 U/L; 43.5 U/L) (S 147 U/L; 59 U/L) (P + S 142 U/L; 59 U/L). Conclusion: The combination of pravastatin + sorafenib were more effective than Sorafenib alone.
publishDate 2012
dc.date.none.fl_str_mv 2012
2012
2012
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10810/7326
url http://hdl.handle.net/10810/7326
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv http://www.cancerci.com/content/12/1/5
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:Addi. Archivo Digital para la Docencia y la Investigación
instname:Universidad del País Vasco
instname_str Universidad del País Vasco
reponame_str Addi. Archivo Digital para la Docencia y la Investigación
collection Addi. Archivo Digital para la Docencia y la Investigación
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412683691851776
score 15,300724

Similares en LA Referencia